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Abstract
A Web-based statistical tool for sample size and power estimation in animal
carcinogenicity studies is presented in this paper. It can be used to provide a design
with sufcient power for detecting a dose-related trend in the occurrence of a tumor
of interest when competing risks are present. The tumors of interest typically are
occult tumors for which the time to tumor onset is not directly observable. It is ap-
plicable to rodent tumorigenicity assays that have either a single terminal sacrice
or multiple (interval) sacrices. The design is achieved by varying sample size per
group, number of sacrices, number of sacriced animals at each interval, if any,
andscheduledtimepointsforsacrice. MonteCarlosimulationiscarriedoutinthis
tool tosimulateexperiments of rodent bioassays because no closed-form solution is
available. Ittakes design parameters forsamplesize andpower estimation asinputs
through the World Wide Web. The core program is written in C and executed in
the background. It communicates with the Web front end via a Component Object
Model interface passing an Extensible Markup Language string. The proposed sta-
1tistical tool is illustrated with an animal study in lung cancer prevention research.
Key Words: Competing risks; Experimental design; Monte Carlo simulation; Mul-
tiple/Single Sacrice.
1 Introduction
Due to easy accessibility, the World Wide Web (WWW) provides an excellent environ-
ment for deploying statistical tools. One major advantage to the users is that statistical
designandanalysiscanbeperformedatanyplacewhereanInternetconnectionis avail-
able. It doesnotrequirethat a useracquire,download,or purchaseastatistical software
to run a program. The technology for the WWW interface has been developed and
applied to various statistical applications (to name a few: Baneld, 1999; Firth, 2000;
West and Ogden, 1997).
AWeb-basedsamplesizeandpowerestimatorusingMonteCarlosimulationispro-
posedinthispaper. Thisstatisticaltoolisdesignedforanimalcarcinogenicity/tumorigenicity
studies on occult tumors, and for rodent bioassays with a single terminal sacrice or
multiple (interval) sacrices. The estimator takes inputs from the WWW through an
ExtensibleMarkupLanguage(XML)interfaceandsimulatesthespecieddesignin the
background. The design input parameters include (a) number of dose groups, (b) type
of experiments with the number of interval sacrices, (c) dose metric in each group,
(d) sample size per group, (e) time points for sacrice, (f) number of sacriced animals
at each interval, (g) tumor onset probability in the control group, (h) shape of tumor
onset distribution, (i) hazard ratio between each dose group and the control group, (j)
competing risks survival rate in each group, (k) parameter to determine lethality rate
in the control group, (l) signicance level of a one- or two-sided test, and (m) number
of simulation runs. This tool sends results back to the user via e-mail. The results
include summary statistics, such as the simulated average tumor onset probability in
eachgroup,thesimulatedaveragecompetingriskssurvivalratepergroup,thesimulated
average tumor lethality rate in each group, along with the design considerations, and
2the estimated power. In this study, the core simulation program is written in C.
Animal carcinogenicity bioassays are routinely used to evaluate the carcinogenic
potential of chemical substances to which humans are exposed. In a typical animal
carcinogenicity study on occult tumors, each animal is assumed to begin with a tumor
free state. Mice or rats are commonly used species. They are randomized into a
controlgroup(typically,animalsthatareexposedtoacontrolagentorobservedwithout
any exposure) or into 2 to 3 test groups that receive specied levels of exposure and
are observed until they either die or are sacriced. In an experiment with multiple
sacrices, sacriced animals are pre-assigned to a specic dose level and sacrice time
at the beginning of the experiment. In a single terminal sacrice, all surviving animals
are sacriced and subjected to necropsyat the end of the experiment,which is typically
a period of 104 weeks (2 years). During the study, age at death and the information
on the presence or absence of the tumor of interest are collected for each animal. The
primarygoaloftheexperimentistoassessadose-relatedtrendoftestagentexposuresin
the incidenceof the tumorof interest. Thetumorof interest canbe anyocculttumorfor
which the time to tumor onset is not directly observable. Our software can also seek a
reduceddesign(78-104weeks)withanacceptablepower. Theproposedstatisticaltool
can also be used to seek an optimal design by choosing the design with the maximum
power of the trend test for a given total sample size. This tool will help researchers
conduct more efcient and cost effective experiments.
ThelogranktestofMantelandHaenszel(1959)maybeusedforcomparinghazards
of death from rapidly lethal tumors. To compare the prevalence of nonlethal tumors,
the prevalence test proposed by Hoel and Walburg (1972) may be used for incidental
tumors. However,thedataobtainedfromacarcinogenicityexperimentgenerallycontain
a combination of fatal and incidental tumors. Peto et al. (1980) suggested combining
the fatal and incidental tests for comparing tumor onset distributions. The procedure
proposed by Peto et al., has been called the cause-of-death test or the Peto test.
The development of the presented statistical tool is motivated by a series of animal
studies at M: D: Anderson Cancer Center that explores the mechanisms underlying the
3chemopreventive effects of test agents. The rst step is to establish the carcinogenic
potentialofthetobaccocarcinogenNNK,abyproductoftobaccosmoke,inretinoicacid
receptor- (RAR-) transgenicmice. The Peto test, recommendedby the International
Agency for Research on Cancer (IARC), is used to compare the tumor incidence rate
among groups in the presence of potential confounders. It is a widely used statistical
test to determinea dose-relatedtrendfora test agentinthe occurrenceof occulttumors.
The purpose of this paper is to present a statistical tool for Web-based sample size
andpowerestimationusingthePetoteststatistictoprovidesufcientpowerfordetecting
a dose-related trend in the occurrence of a tumor of interest. This package simulates
rodent bioassay experiments with either a single sacrice or multiple sacrices. A
comprehensivelistofdesignparameterscanbespeciedbytheusersthroughtheWWW.
The underlying models are described in Section 2. A detailed description of the use
of the proposed estimator is demonstrated in Section 3. A design of a carcinogenesis
experimentforlungcancerpreventionresearchis illustratedinSection 4as anexample.
Concluding remarks and suggested future study directions are described in the last
section.
2 Model and Test for a Sample Size and Power Estima-
tor
Consideracarcinogenicity/tumorigenicityexperimentwiththecontrolgroupand G 1
dose groups of animals. Suppose that Ni animals are randomly assigned to the i-th
group, and they are followed over time for the development of irreversible and occult
tumors. The animals in the i-th group receive a dose level of `i of a test agent. We
assume that all animals come from the same populationand have no tumor on day zero
of the experiment. The time scale is divided into J intervals such that the j-th interval
is given by Ij D .tj 1;tjU; j D 1;:::; J. Note that t0 D 0 and tj denotes sacrice
timepointfor j D 1;:::; J. Foranexperimentwitheitherasinglesacriceormultiple
4sacrices, tJ denotes the terminal sacrice time point.
It is assumed that three independent random variables completely determine the
observed outcome for each animal. The random variables are the time to onset of
tumor, T1; the time after onset until death from the tumor, T2; and the time to death
from competing risks, TC. Also let T1 C T2 D TD, where TD represents the overall
time to death from the tumor of interest. Thus the tumor of interest is present in an
animal at the time of death if T1  minfTC;TSg, where TS denotes a scheduled time
to sacrice of an animal. When TD  minfTC;TSg, an animal dies from the tumor of
interest. Otherwise, it dies from competing risks or sacrice.
2.1 Distribution of the Random Variables
 Time to tumor onset (T1)
Let Si.t/ be a survival function of the i-th group with respect to a random variable
T1 representing time to onset of the tumor of interest. Assume Si.t/ follows a Weibull
distribution: Si.t/ D exp

 i1.t=tmax/2
; (1)
where 1  0, 2  0, and tmax represents the duration of the study or the time for a
terminalsacrice. Thehazardratioi betweenthei-thdosegroupandthecontrolgroup
(i D 1) is typically greaterthan or equal to 1 (i D 1 fori D 1 and i > 1 fori > 1) for
i D 1;:::;G. The scale parameter 1 can be calculated by specifying the tumor onset
probability1  S1.tmax/ at the end of the study in the control group. With 1 D 1 and a
given shape parameter 2; 1 D  logS1.tmax/. In this estimator, we allow the value of
the parameter 2 of the Weibull distribution for rangingbetween 1:0 and 6:0 in order to
reect a wide variety of tumor onset distributions. When there are no competing risks,
the tumor onset probability at the end of the study in each dose group is determined by
thehazardratioandthe baseline tumoronset probabilityin the controlgroupbythe end
of the study.
 Time to death from competing risks (TC)
5The survival function for time to death from competing risks, TC, is taken to be
Qi.t/ D exp

 i.1t C 2t3/

; (2)
where i  1; 1  0; 2  0 and 3  0 (Portier et al., 1986). With 1 D 1 in the
control group (i D 1), 3 can be calculated as
log

 flog Q1.tmax/ C 1tmaxg=2

=logtmax
under the constraint that Q1.tmax/ < exp. 1tmax/, where Q1.tmax/ is the probability
of survival with respect to competing risks in the control group at the end of the study.
The values of 1 and 2 are chosen as 10 4 and 10 16, respectively. These values are
close to the ones tted to the historical controldata such as Fisher 344 rats andB6C3F1
mice in Portier et al. (1986). These parameter values can be also found in many other
settings (Kodell and Ahn, 1996, 1997; Kodell et al., 1997; Ahn, Zhu and Yang, 1998;
Ahn et al., 2002). The competing risks survival rate can be determined according to
tumor types and historical data showing the survival rates of mice and rats. The value
ofi canbe calculatedafterspecifyingthecompetingrisks survivalrate Qi.tmax/ in(2)
such that i D log[Qi.tmax/]=logTQ1.tmax/U.
 Time to tumor death (T2)
For simplicity, the survival distribution for tumor-induced mortality, T2, is taken to
have the same form as that for death from competing risks
Fi.t/ D exp

  i.1t C 2t3/

; (3)
and the values of 1; 2 and 3 remain the same as in (2). These types of models
using a modied Weibull distribution can be found in other literature (Kodell, Chen
and Moore, 1994; Ahn and Kodell, 1995; Kodell and Ahn, 1997). The parameter  1 is
selected by the user to reect various tumor lethalities from low tumor lethality (where
approximately 5% of observed tumors are the cause of death) to high tumor lethality
(where approximately 60% or higher of observed tumors are the cause of death) in the
control group. We also assume that once the tumor is developed, the distribution of
time to death (T2) is the same in all dose groups. Therefore,  i D 1 for all i. The
lethality parameter indicates how the presence of a tumor of interest affects survival. A
highly lethal tumor could lead to death shortly after its onset. Less restrictive choices
for the distribution of T2 can also be considered.
62.2 Construction of the Peto Test
The data are generated according to the distributions of T1, T2 and TC for each animal.
They are collected at the j-th interval according to the following ve events: animals
died from the tumor of interest (dj), animals died from competing risks while having
the tumor of interest (a1j), animals died without tumor (b1j), animals sacriced with
tumor(a2j),andanimalssacricedwithouttumor(b2j). Ananimaldiesfromthetumor
of interest in the j-th interval if TD 2 Ij and TC > TD. An animal dies from other
causeswiththetumorofinterestinthe j-thintervalif TD > TC; T1  TC;and TC 2 Ij.
On the other hand, an animal dies without the tumor of interest in the j-th interval if
TC 2 Ij and T1 > TC. A sacriced animal has the tumor of interest at the time of
sacrice (tj) if T1  tj; TD > tj; and TC > tj. It does nothave the tumorat the time of
sacrice when T1 > tj and TC > tj. These data are applied to the Peto test to estimate
sample size and power.
First, consider the animals that did not have the specic tumor before death or
tumor-bearing animals for which that tumor was not the cause of death. Let nij D
a1ij C a2ij C b1ij C b2ij be the number of animals in group i dying during interval Ij
fromcausesunrelatedtothepresenceofthetumorofinterest,andlet yij D a1ij Ca2ij be
the numberof these animals in which the tumor was observedin the incidental context,
fori D 1;:::;G and j D 1;:::; J. Foreachinterval Ij,thetumorprevalencedatamay
besummarizedina2G table,asinTable 1. Alltumorsfoundinsacricedanimalsare
classied as incidental. The intervalsdened bythe pre-assignedNTP intervals(Bailer
and Portier, 1988) are recommended to implement the incidental part of the Peto test.
Theexpectednumberoftumorsinthei-thgroupforthe j-thintervalis Eij D y:jKij,
where Kij D nij=n:j. Thus, the observed and expected numbers of tumors in the i-th
groupovertheentireexperimentare Oi D
PJ
jD1 yij and Ei D
PJ
jD1 Eij, respectively,
for i D 1;:::;G. Dene
Di D Oi   Ei D
J X
jD1
.yij   Eij/
and
Vri D
J X
jD1
jKrj.ri   Kij/;
7Table 1: Tumor prevalence data for incidental tumors in interval Ij
Dose group
1 2  G Total
# with tumors y1j y2j  yGj y:j
# without tumors n1j   y1j n2j   y2j  nGj   yGj n:j   y:j
# deaths n1j n2j  nGj n:j
Table 2: Tumor mortality data for interval Ij
Dose group
1 2  G Total
# fatal tumor deaths in Ij x1j x2j  xGj x:j
m1j   x1j m2j   x2j  mGj   xGj m:j   x:j
# surviving in Ij m1j m2j  mGj m:j
where j D y:j.n:j   y:j/=.n:j   1/; and ri is dened as 1 if r D i and 0 otherwise.
Let Da = .D1;:::; DG/T; and Va be the G  G matrix with (r;i) entry Vri.
Second,considertheanimalsthatdiedwithatumorofinterest. Themethodusedfor
thefataltumorsissimilartothatusedfortheincidentaltumors. Table 2isacontingency
table fortumormortalitydata in the j-thinterval. Data-determinedintervalsdenedby
the actualdeath time ofan animal wereused forthe fatal tumoranalysis. Let mij be the
number of animals in group i surviving at the beginning of the interval, and xij D dij
be the number of these animals dying from the tumor of interest in that interval. A
vector Db that has the differences of observed and expected values using the data in
Table2iscalculatedinthesamewayasfortheincidentaltumors,andthecorresponding
covariance matrix Vb is computed.
The analysis of data on occult tumors using contexts of observation is based on the
vector D = Da + Db, with covariance matrix V D Va C Vb. Then a dose-related trend
test can be considered by using
8ZR D lT D=
p
lT Vl;
where l D .`1;:::;`G/T, and `i stands for the dose metric for the i-th group with
0 D `1 < `2 < ::: < `G. Under the null hypothesis, ZR is asymptotically distributed
as a standard normal.
3 Usage of Sample Size and Power Estimator
The proposedestimator for sample size and power takes input parameters from a series
of pages in the Web site (http://biostatistics.mdanderson.org/ACSS). The title page in
Figure 1 provides a general description of the proposed estimator. By clicking the
Continue button, it moves to a user log-in and registration page, as shown in Figure 2.
A new user is required to register to obtain a user name and a password.
Users maysave orretrievetheir workby enteringorselecting a le name. Fora test
run, the session may remain as default, as shown in Figure 3. A default session name
automaticallygeneratedbyconcatenatingthe username, date andtime is provided,and
it shall be used as the subject of an e-mail for delivering the output. The session
name may be changed as the user wishes. Figure 4 shows a page of the detailed input
parameters in an experimental design. It starts with requesting three input parameters
(a) the number of dose groups, (b) whether the experiment uses multiple sacrices or
a single terminal sacrice, and (c) an integer seed for the random number generator.
The number of dose (or treatment) groups commonly considered are 2 to 4 groups,
including the control group. An experiment with multiple sacrices is simulated to
perform sacrices at specied interim time points, as well as a terminal sacrice at
the end of the study. All the remaining live animals are assumed to be sacriced at
the end of the experiment. The number of scheduled sacrices, including the terminal
sacrice,is typicallyeither3or4inatwo-yearstudy. Inaddition,aseedfortherandom
numbergeneratorcan be chosenby the user as any positive integer for the Monte Carlo
simulation.
Figure 5 shows other detailed input parameters, which are (a) dose metric in each
9Figure 1: A general description of the proposed estimator
10Figure 2: A user log-in page
Figure 3: The rst input page
11Figure 4: Input parameters on the sample size and power estimation
12group, (b) sample size per group, (c) sacrice time points, (d) number of sacriced
animalsattheendofeachtimeinterval,(e)tumoronsetprobabilityinthecontrolgroup,
(f) shape parameter of the Weibull distribution for time to tumor onset, (g) hazard ratio
between each dose group and the control group, (h) competing risks survival rate per
group, (i) tumor lethality rate (low, intermediate, and high), (j) value of the lethality
parametertodeterminealethalityrateinthecontrolgroup,(k)signicancelevelofone-
or two-sided test, and (l) number of simulation runs. Typically, animal carcinogenicity
studies on occult tumors are conducted in a duration of 104 weeks. This statistical tool
can also seek an efcient reduced design (78 - 104 weeks) with an acceptable power.
ThedefaultvaluesareshowninFigures 3-5foratypicaltwo-yearbioassayexperiment
that has multiple sacrices. For a design with 4 groups, the dose levels may be set
as a relative dose metric of 0, 1, 2 and 3 or 0, 1, 2 and 4 with respect to the control
and 3 dose groups. Alternatively, the actual dose levels may be used in a design. In a
typicaltwo-yearanimalcarcinogenicitystudyon occulttumors,50ormoreanimals are
considered in a group. However, a different number of animals per group may be used
in a design. One needs to specify the time points of sacrices in weeks. For a two-year
study, NTP intervals are, for example, 0 - 52, 53 - 78, 79 - 92, and 93 - 104 weeks. For
analyzingsingle-sacricedatawiththePetotest (describedinSection 2), NTPintervals
were used for the incidental tumors. The NTP intervals for a two-year study are given
as a default. The number of sacriced animals is decided at the beginning of a study.
Either the same number of sacriced animals or a different number of animals can be
specied in each group and/or each interval.
Theprobabilityoftumoronsetbytheendofthestudyinthecontrolgroupneedstobe
specied in a design to determinethe time to tumoronset. A tumoronset probabilityof
eachdosegroup,therefore,isdeterminedbyahazardratioandatumoronsetprobability
in the control group. An underlying distribution of time to tumor onset is assumed to
be a Weibull distribution (Kodell and Ahn, 1997). The shape parameter in the Weibull
tumor onset distribution ranges between 1.0 (exponential distribution) and 6.0 in order
to reect a wide variety of tumor onset distributions. The hazard ratio is a ratio of
13Figure 5: More input parameters on the sample size and power estimation
14hazardrates betweena dosegroupandthe controlgroup. A user needsto specify G 1
hazardratios,whereG isthenumberofgroups,intheestimationofsamplesizetohavea
desirabledegreeofpowertodetectaspeciedhazardratio. Intercurrentmortalityrefers
to all deaths not related to tumors of interest. The causes of intercurrent mortality are
referredto as competingrisks. Since a specic typeof tumormayoccurin the presence
of competing risks, intercurrent mortality rates (competing risks survival/death rates)
are considered in our design. They may be the same or different across dose groups.
Thelethalityparameterneedstobesettogovernthetumorlethalityrateinthecontrol
group. Three tumor lethality rates (low, intermediate and high) are considered in this
paper. Tumorsoflowlethalitygenerallyhaveratesbelow10%. Tumorsofintermediate
lethalityaretypicallythosewithratesbetween35%and40%. Therates 60%andabove
are considered as highly lethal. To facilitate the choice of a tumor lethality parameter,
reference table(s), depending on study duration, tumor onset probability and tumor
onset distribution, will be shown in a separate window by clicking the Help button in
the section describing the tumor lethality parameter illustrated in Figure 5. The table
entries are obtained from a database that stores the information of a wide range of
lethality rates by the duration of the study, tumor rate and tumor onset distribution.
The value of a lethality parameter, then, can be chosen from the reference tables. A
referencetableisshowninFigure6asanexample. Tables35containparametervalues
to reect tumor lethality. These values are predetermined by a numerical method for
a simulation model similar to (1)(3) in Section 2.1 because there is no a closed-form
solution to obtain the lethality parameter values.
The signicance level of the test typically can be specied 1%, 5% or 10%. The
choice of a one- or two-sided test is also needed to estimate power. The numberof data
sets (i.e., simulation runs) needs to be decided for the Monte Carlo simulation. In this
example, 5000 simulation runs are given as a default value. The e-mail address of the
user is required to receive simulated results via e-mail.
Before submitting input parameters, all design parametersare displayed once again
on the Web page for verication (See Figure 7). Once all the input parameters entered
15Figure 5: More input parameters on the sample size and power estimation (continued)
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17Figure 7: Input parameters considered (continued)
are conrmed, they are submitted to the compiled C program for simulation runs.
When the simulation runs are completed, an output le is sent to the e-mail address
specied by the user. A simulation with 5000 runs typically takes about 5 minutes.
The output le contains design parameters, average tumor rate, average competing
risks survival rate, average lethality rate for each group, and average death rate with
information on tumors and sacrices per dose group. At the end, the power to detect a
dose-related trend is shown. Figure 8 shows an image of the output le generated from
the above example.
4 Example: Testing the Carcinogenic Potential of NNK
in a Prevention Study for Lung Cancer
Thedevelopmentofthisstatisticaltoolwasmotivatedbyarecentlungcancerprevention
study developed at M: D: Anderson Cancer Center. One particular goal was to evalu-
18Figure 8: Contents of an output le
19Figure 8: Contents of an output le (continued)
20ate the carcinogenic potential of the tobacco carcinogen NNK, a byproduct of tobacco
smoke,ontheincidenceoflungadenomasandadenocarcinomas(occurringeitherspon-
taneously or following exposure to the tobacco carcinogen NNK) in transgenic mice
that express antisense retinoicacid receptor- (RAR-). A Web-basedsample size and
power estimator was applied to provide sufcient power to detect a dose-related trend
of the occurrence of lung adenomas and adenocarcinomas. The estimation of sample
size and power was conducted by the Peto test (see Section 2).
The power computation is based on the following assumptions. One hundred anti-
sense RAR- hemizygous (+/0) mice and one hundred antisense RAR- homozygous
(+/+) mice will be obtained for the experiments. For each type of mice, fty mice will
be randomized into a group that either receives or does not receive exposure to NNK.
To test thecarcinogenicpotentialof NNK, a dose metricof 0 or1 is used forthe control
group or exposed group, respectively. Serial sacrices are scheduled at weeks 39, 52,
65, and 78 (at the end of the study). The time to lung cancer development is assumed
to follow a Weibull distribution with the shape parameter 3. It is expected that 55% of
the antisense RAR- hemizygousmice will developa lungcancerby 78weeks. On the
other hand, 86% of the antisense RAR- homozygous mice are expected to develop a
lung cancer by 78 weeks. In this experimental design, 85% competing risks survival
rate is considered. The lung adenomas and adenocarcinomas are assumed to be highly
lethal. Five thousand simulation trials are run.
The statistical power (in %) under the one-sided 5% nominal signicance level is
listed in Table 6. A hazard ratio between the treatment group and the control group in
each type of mice is chosen as 2:0, 2:5 and 3:0. Three different designs are considered.
One is to estimate power with 6 mice at each serial sacrice (39, 52 and 65 weeks) in
a total of 50 mice per group. Another setting is to calculate power with 6 sacrices at
52 weeks out of a total of 55 in the control group and with 3 sacrices at 52 weeks out
of a total of 45 in the dose group. The other conguration is to estimate power with
a total of 30 mice per group and 3 mice per serial sacrice at 39, 52 and 65 weeks.
The same competing risks survival rate (85% for the control and a dose group) and
21different competing risks survival rates (85% for the control, 50% for a dose group)
are considered in this example. Under the null hypothesis of no treatment effect on the
tumor of interest, it may still be reasonable to assume different competing risk rates
among different dose groups. For example, even though the carcinogen may have no
effect on the development of lung cancer, it may increase competing risks, such as the
development of a liver tumor or bladder tumor, etc, and, consequently, results in lower
competingrisks survivalrates in the dose groups. A lungcancer is typicallyconsidered
as highly lethal in humans. The median survival time is less than a year for stage III
and less than 6 months for stage IV non-small cell lung cancer (Ginsberg et al., 1993).
Lethality parameters of 1500 and 800 are selected in hemizygous and homozygous
mice, respectively, to reect highly lethal tumors. Expected lethality corresponding to
these parameters is about 80% in this example.
With 50 hemizygousmice in each groupand the same competingrisks survival rate
between groups, 79:9% power was achievedto detect a hazard ratio of 2. However, the
power decreased slightly to 75:8% with different competing risks survival rates. On
the other hand, at least 80% power was achieved with 50 homozygous mice in each
group. With 30 mice in each group of hemizygous and homozygous mice, we had
less than 80% power to detect a hazard ratio of 2 in the presence of both the same and
different intercurrent mortalities. A better design, in this example, was achieved with
the control group of 6 mice for an interim sacrice at 52 weeks out of 55 mice in total,
and with a treatment group of 3 mice for an interim sacrice at 52 weeks out of 45
mice in total. In this design, 80% power was achieved to detect a hazard ratio of 2 or
higher among antisense RAR- hemizygous and homozygousmice with the same and
different competing risks survival rates.
5 Discussion
Wehavedeveloped,basedonourknowledge,therstWeb-basedsamplesizeandpower
simulator for animal carcinogenicity studies to detect a dose-related trend in tumor
22incidence following exposure to a putative carcinogen. It is applicable for studies on
occult tumors for which the time to tumor onset is not directly observable. It was
designed for rodent bioassays that have either multiple sacrices or a single terminal
sacrice.
ThePetotest(Petoetal:,1980)isusedtocomparetheincidencerateofocculttumors
among groups in the presence of potential confounders. It requires data with cause-of-
deathinformationdeterminedbypathologists. Monte Carlo simulationis introducedin
this tool to simulate experiments of rodent bioassays because no closed-form solution
is available.
This package could be used to construct a design with a sufcient power to detect
specied hazard ratios by varying the sample size, number of sacrices, time points
for sacrice, and number of sacriced animals at each sacrice, if any, under the given
design considerations. As an example, the application of this tool was illustrated by an
animal experiment for lung cancer prevention research. An advantage of the proposed
Web-based sample size and power estimator is wider accessibility to the user, provided
thatanInternetconnectionandaWebbrowserareavailable(MicrosoftInternetExplorer
5:5 and above, or Netscape 4:76 and above). In addition, this statistical tool provides a
user-friendly environment so that the user can search for an optimal design.
Figure 9 shows a owchart for the communication between the Web front end and
the core program. Input data are supplied to the proposed tool via a user-interface
implementedwithWeb pages. When theuser presses the Submitbuttonon thelast Web
page, the user input is captured by the Web application and packaged into XML string
format (see packSimDataIntoXML.inc JavaScript le in Appendix A.1). Then,
it is sent to a queue implemented by a Perl module (see xprocessOutputR.asp
in Appendix A.2) for temporary storage until the time at which it can be scheduled
for processing by the calculation kernel program. Every few minutes a Queue Reader
processrunningonaseparatecompute-servermachinescansthequeueforwaitinginput
data. When new data is found, it is sent (still in XML format) to the calculation kernel
program. This returns the results to the Queue Reader. The Queue Reader then sends
23the results to the user via e-mail. This asynchronous queued architecture is chosen
so that multiple jobs requiring calculation times ranging from a few seconds to several
hours could be accommodated. The communication with the queue is done through a
custom software component implemented with Microsoft's Component Object Model
(COM)technology. Thisallowstheactualqueue(arelationaldatabase)tobeabstracted
from the remainder of the system, so that the queue can be changed/upgraded without
requiring additional maintenance on the rest of the system.
Figure 10 shows a communication data-ow diagram inside the ACSS calculation
programinFigure9. InsidetheexecutabletheXMLstringisprocessedinProcessIOFunc
and ComposeStruct functions. The latter calls the XML parser from an external
XML Parsing Library and initializes the XMLInputStruct, which is passed as an
input parameter to the ACSSFunc function.
Through a Monte Carlo simulation study, the proposed tool can seek an efcient
design. For a given sample size and study duration, an optimal design can be obtained
using our tool by choosing the design with the maximum power of the trend test. This
tool can help investigators conduct more efcient and cost effective experiments.
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26A Appendix
A.1 packSimDataIntoXML.inc JavaScript le
<%
// Pack the data for the current simulation into an XML string
function packSimDataIntoXML()
{
var xml = "<acss ";
xml += "numgroups = `x1' ";
xml += "numsacrifices = `x2' ";
xml += "studyduration = `x3' " ;
xml += "tumoronsetprob = `x4' ";
xml += "shapeparameter = `x5' ";
xml += "lethalityrate = `x6' ";
xml += "tumorlethalityparameter = `x7' ";
xml += "numdatasets = `x8' ";
xml += "testlevel = `x9' ";
xml += "testsides = `k1' ";
xml += "seed = `k2' ";
xml += "multiplicity = `k3' ";
xml += "sessionName = `k4'>";
xml = xml.replace(/x1/, Session("NumDoseGroups"));
xml = xml.replace(/x2/, Session("NumSacrifices"));
xml = xml.replace(/x3/, Session("StudyDuration"));
xml = xml.replace(/x4/, Session("TumorOnsetProb"));
xml = xml.replace(/x5/, Session("ShapeParameter"));
xml = xml.replace(/x6/, Session("LethalityRate"));
xml = xml.replace(/x7/, Session("TumorLethalityParameter"));
xml = xml.replace(/x8/, Session("NumDataSets"));
xml = xml.replace(/x9/, Session("TestLevel"));
27xml = xml.replace(/k1/, Session("TestSides"));
xml = xml.replace(/k2/, Session("FixedSeed"));
xml = xml.replace(/k3/, Session("Experiments"));
xml = xml.replace(/k4/, Session("sessionName"));
var i, temp, length;
var groupTemplate = "<group crsr=`xx' DoseMetric =`zz' num=`yy'
NumPerGroup=`ff' />";
for (i = 0; i < Session("NumDoseGroups"); i++)
{
temp = groupTemplate.replace(/xx/, Session("crsr" + i));
temp = temp.replace(/zz/,Session("DoseMetric"+i));
temp = temp.replace(/ff/, Session("NumPerGroup"+i));
xml += temp.replace(/yy/, i);
}
var groupHazardTemplate = "<hazardgroup HazardRate =`xx' />";
for (i = 1; i < Session("NumDoseGroups"); i++)
{
temp = groupHazardTemplate.replace(/xx/, Session("HazardRate"
+ i));
xml += temp;
}
var sacrificeTemplate = "<sacrifice SacrificeTimes=`yy' num=`zz'/>";
for (i = 1; i <= Session("NumSacrifices")-1; i++)
{
temp = sacrificeTemplate.replace(/yy/, Session("SacrificeTimes"+i));
xml += temp.replace(/zz/, i);
}
28var interimSacrificesTemplate = "<interimsacrifices numInterimSacrifices
=`xx' />";
length = Session("NumDoseGroups")*(Session("NumSacrifices")-1);
for (i = 0; i < length ; i++)
{
temp = interimSacrificesTemplate.replace(/xx/, Session("InterimSacrificeTimes"
+ i));
xml += temp;
}
var emailTemplate = "<guestemail email=`xx' />";
xml += emailTemplate.replace(/xx/,Session("Email"));
xml += "</acss>";
return xml;
}
%>
A.2 xprocessOutputR.asp
<%@ Language=JScript %>
<%
var xmlInput,UserEmail,iHandlerID;
.....
if ("" + Request.Form("Submit") != "undefined")
{
UserEmail = Session("Email");
xmlInput = Session("xml");
iHandlerID = myQ.Constants("eACSS");
iMsgID = myQ.postMsg(iHandlerID, UserEmail, xmlInput);
29if ( iMsgID == myQ.Constants("eINVALID_ID"))
{
Response.Redirect ("simStartError.asp");
}
else
{
Response.Redirect ("ACSS_Acknowledge.asp");
}
myQ = "" ;
}
%>
30Table 3: Reference table for the parameter values for selecting low tumor lethality
(< 10%)
Weibull-1.0a Weibull-3.0 Weibull-6.0
Tumor Rate 78b 104 78 104 78 104
.05 2.50 2.00 25.0 20.0 50.0 40.0
.10 2.40 1.90 24.0 19.0 45.0 39.0
.15 2.30 1.80 23.0 18.0 43.0 38.0
.20 2.20 1.70 22.0 17.0 42.0 37.0
.25 2.10 1.60 21.0 16.0 41.0 36.5
.30 2.00 1.50 20.0 15.0 40.0 36.0
.35 1.90 1.40 19.0 14.0 39.5 35.5
.40 1.80 1.30 18.0 13.0 39.0 35.0
.45 1.70 1.20 17.0 12.0 38.5 34.5
.50 1.60 1.10 16.0 11.0 38.0 34.0
.55 1.50 1.05 15.0 10.5 37.5 33.4
.60 1.45 1.00 14.0 10.0 37.0 32.8
.65 1.40 0.95 13.0 9.5 36.0 32.2
.70 1.35 0.93 12.0 9.0 35.0 31.5
.75 1.30 0.90 11.0 8.7 34.0 30.5
.80 1.25 0.87 10.0 8.5 33.0 29.0
.85 1.20 0.84 9.0 8.3 32.0 27.0
.90 1.15 0.80 8.5 8.0 31.0 25.0
.95 1.10 0.70 8.0 7.5 30.0 23.0
aTumor onset distributions; bStudy duration in weeks
31Table 4: Reference table for the parameter values for selecting intermediate tumor
lethality ( 40%)
Weibull-1.0a Weibull-3.0 Weibull-6.0
Tumor Rate 78b 104 78 104 78 104
.05 40.0 25.0 250.0 200.0 500.0 400.0
.10 39.0 24.0 240.0 190.0 450.0 390.0
.15 38.0 23.0 230.0 180.0 440.0 380.0
.20 37.0 22.0 220.0 170.0 435.0 370.0
.25 36.0 21.5 210.0 160.0 430.0 360.0
.30 35.0 21.0 200.0 150.0 425.0 350.0
.35 34.0 20.5 195.0 145.0 420.0 340.0
.40 31.0 20.0 192.0 143.0 415.0 330.0
.45 28.0 19.0 190.0 140.0 410.0 320.0
.50 26.0 18.0 186.0 137.0 405.0 310.0
.55 24.0 17.0 182.0 135.0 400.0 300.0
.60 22.0 16.0 178.0 132.0 390.0 285.0
.65 21.0 15.0 174.0 130.0 380.0 270.0
.70 20.0 14.0 170.0 127.0 370.0 260.0
.75 19.0 13.0 165.0 124.0 360.0 250.0
.80 18.0 11.0 160.0 120.0 340.0 240.0
.85 17.0 10.0 150.0 110.0 320.0 230.0
.90 13.0 8.0 130.0 100.0 300.0 220.0
.95 10.0 6.0 100.0 80.0 250.0 210.0
aTumor onset distributions; bStudy duration in weeks
32Table 5: Reference table for the parameter values for selecting high tumor lethality
(> 60%)
Weibull-1.0a Weibull-3.0 Weibull-6.0
Tumor Rate 78b 104 78 104 78 104
.05 300.0 250.0 2500.0 2000.0 4000.0 2800.0
.10 295.0 245.0 2400.0 1900.0 3500.0 2600.0
.15 290.0 240.0 2300.0 1800.0 3000.0 2400.0
.20 288.0 230.0 2200.0 1700.0 2800.0 2200.0
.25 285.0 220.0 2100.0 1600.0 2750.0 2100.0
.30 283.0 210.0 2000.0 1500.0 2700.0 2000.0
.35 280.0 200.0 1900.0 1400.0 2650.0 1900.0
.40 278.0 190.0 1800.0 1300.0 2600.0 1850.0
.45 275.0 180.0 1700.0 1200.0 2550.0 1800.0
.50 270.0 170.0 1600.0 1100.0 2500.0 1750.0
.55 265.0 160.0 1500.0 1000.0 2450.0 1700.0
.60 260.0 150.0 1400.0 900.0 2400.0 1650.0
.65 250.0 140.0 1300.0 800.0 2300.0 1600.0
.70 240.0 130.0 1200.0 700.0 2200.0 1550.0
.75 210.0 120.0 1100.0 650.0 2100.0 1500.0
.80 180.0 110.0 900.0 600.0 2000.0 1400.0
.85 150.0 100.0 800.0 550.0 1800.0 1200.0
.90 110.0 80.0 700.0 500.0 1600.0 1050.0
.95 70.0 60.0 600.0 400.0 1400.0 900.0
aTumor onset distributions; bStudy duration in weeks
33Table 6: Power calculation for animal carcinogenicity studies of NNK in Antisense
RAR- mice
Type of mice CRSRa Hazard ratio (6,50)b (6,55,3,45)c (3,30)d
Antisense RAR- 2.0 79.9 84.6 61.2
hemizygous (+/0) samee 2.5 95.4 97.4 84.4
mice 3.0 99.2 99.7 94.2
2.0 75.8 80.4 57.9
differentf 2.5 94.0 96.0 81.8
3.0 98.9 99.5 92.8
Antisense RAR- 2.0 84.8 87.8 66.1
homozygous (+/+) same 2.5 97.2 97.7 85.2
mice 3.0 99.3 99.7 93.6
2.0 82.8 84.7 63.5
different 2.5 96.4 96.8 83.6
3.0 99.2 99.4 93.0
aCompeting Risks Survival Rate
b6 mice at each serial sacrice (39, 52, 65 weeks) and a total of 50 mice per group
c6 mice at an interim sacrice (52 weeks) and a total of 55 mice (control group);
3 mice at an interim sacrice (52 weeks) and a total of 45 mice (dose group)
d3 mice at each serial sacrice (39, 52, 65 weeks) and a total of 30 mice per group
e85% CRSR for the control and a dose group
f 85% CRSR for the control and 50% CRSR for a dose group
34Figure9: Aowchartforthecommunicationbetweenthefrontendandthecoreprogram
35Figure 10: A data-ow diagram inside ACSS calculation program in Figure 9.
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